An international coalition of scientists is calling for immediate regulatory action on glyphosate, the world's most widely used herbicide, citing strengthening evidence linking the chemical to cancer and other serious health impacts.
The scientists' statement, published this week, synthesizes recent epidemiological studies, toxicological data, and mechanistic research that collectively point to non-Hodgkin lymphoma as well as potential risks for other malignancies. The intervention represents a significant escalation in the decades-long scientific and regulatory debate over glyphosate safety.
Glyphosate, marketed most famously as Roundup by Bayer (which acquired Monsanto in 2018), is applied to hundreds of millions of acres annually worldwide. The chemical is integral to industrial agriculture, particularly for genetically modified crops engineered to tolerate herbicide application. Residues are routinely detected in food, water, and human urine samples.
What makes this scientific consensus statement particularly significant is its timing and scope. While the International Agency for Research on Cancer (IARC) classified glyphosate as "probably carcinogenic to humans" in 2015, regulatory agencies in the United States and European Union have largely maintained that the herbicide is safe when used as directed. This new statement directly challenges that regulatory stance.
"The evidence has reached a tipping point," said Dr. Nathan Donley, environmental health science director at the Center for Biological Diversity and one of the statement's organizers. "We now have multiple independent lines of evidence — epidemiological, animal studies, and mechanistic data on DNA damage — all pointing in the same direction. Regulators can no longer dismiss these findings as inconclusive."
The chemical industry has fiercely contested cancer links for years, spending hundreds of millions on legal defenses after thousands of plaintiffs — many of them agricultural workers and landscapers — filed lawsuits alleging glyphosate caused their lymphomas. Bayer has paid out over $10 billion in settlements while continuing to maintain the product's safety and keep it on the market.
